ABI-6250 clinical trials

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

This study is looking at a new medicine called ABI-6250 for people with chronic hepatitis D (HDV) infection. Researchers want to see if it's safe, how it works in the body, and if it helps treat the infection. It's a Phase 2 trial, meaning it's still in the earlier stages of testing.